Hansa Biopharma
Hansa Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company has pioneered a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, primarily used for desensitizing highly sensitized kidney transplant patients. Hansa's proprietary IgG-cleaving enzyme technology platform supports its drug discovery and development pipeline, targeting transplantation, autoimmune diseases, gene therapy, and new therapies. Headquartered in Lund, Sweden, Hansa operates in Europe and the U.S., aiming to address areas with limited treatment options.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueIncludes therapies for kidney transplant desensitization.
Therapies targeting autoimmune conditions.
Pre-treatment solutions for gene therapy applications.
Development of novel treatments for rare conditions.
Customers
Hansa Biopharma's customer base primarily includes healthcare providers and institutions involved in organ transplantation and treatment of rare immunological conditions. The company's products are critical for highly sensitized kidney transplant patients, offering a unique solution where traditional options are limited. Additionally, Hansa collaborates with gene therapy companies to enhance treatment efficacy for patients with pre-existing antibodies. The focus on rare and underserved conditions attracts specialized healthcare providers seeking innovative solutions for complex medical challenges.
Purchase IDEFIRIX for desensitizing kidney transplant patients.
Use therapies for treating complex autoimmune conditions.
Collaborate for pre-treatment solutions to enhance gene therapy.
Strategy
Hansa Biopharma's strategic priorities include advancing its clinical pipeline across core therapeutic areas such as transplantation, autoimmune diseases, and gene therapy. The company aims to expand the use of its IgG-cleaving enzyme technology to address unmet medical needs. Hansa is also focused on strengthening partnerships with gene therapy companies to enhance treatment efficacy. The strategic direction emphasizes innovation and collaboration to maintain a competitive edge in the biopharmaceutical industry.
To address unmet medical needs in core therapeutic areas.
To enhance treatment efficacy in gene therapy.
Geography
Hansa Biopharma is headquartered in Lund, Sweden, with significant operations in Europe and the United States. The company focuses on markets where there is a high demand for innovative treatments for rare conditions, particularly in regions with advanced healthcare systems. Hansa's presence in these key markets allows it to collaborate with leading healthcare institutions and gene therapy companies. The geographic focus supports the company's strategic aim to address unmet medical needs in transplantation and autoimmune diseases.
Risks
Hansa Biopharma faces several business and financial risks, including the inherent uncertainties in drug development and regulatory approval processes. The company's reliance on successful clinical trials and partnerships for revenue generation poses a risk if expected outcomes are not achieved. Additionally, fluctuations in product sales due to the unpredictable nature of organ allocation systems can impact financial performance. Industry-specific risks include competition from other biopharmaceutical companies and potential changes in healthcare regulations.
- Drug Development UncertaintyImpact: CriticalLikelihood: High
Clinical trials may not achieve expected outcomes.
- Sales FluctuationsImpact: HighLikelihood: Medium
Organ allocation systems impact product sales.
Accounting
Judgemental itemsTiming impacts reported earnings.
Impact: high
Affects long-term financial performance.
Impact: medium
Similar listed companies
Publicly listed companies with a comparable business focus.
Cantargia
CANTA · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
Immunic, Inc
IMUX · Pharmaceutical Preparations
Cue Biopharma, Inc.
CUE · Pharmaceutical Preparations
Cue Biopharma is a clinical-stage biopharmaceutical company developing injectable precision immunotherapies designed to selectively modulate disease-relevant T cells.
ADMA Biologics Inc
ADMA · Biological Products, (No Diagnostic Substances)
SAB Biotherapeutics, Inc.
SABSW · Biological Products, (No Diagnostic Substances)
Regen BioPharma Inc
RGBPP · Pharmaceutical Preparations
Regen BioPharma Inc is a U.S.-based biopharmaceutical development company organized in Nevada and operating through its wholly owned subsidiary KCL Therapeutics, Inc.
Last updated: 24/09/2026